Cushing's Disease
Pipeline by Development Stage
Drug Modality Breakdown
Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.
Key Trends
- Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
- Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
- Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus
Career Verdict
Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | FORTEO (TERIPARATIDE) | Eli Lilly and Company | $425M | 30% | LOE_APPROACHING | Declining | |
| 2 | SYNTHROID (LEVOTHYROXINE SODIUM) | AbbVie | $355M | 25% | LOE_APPROACHING | Declining | |
| 3 | ORGOVYX (RELUGOLIX) | Sumitomo Dainippon Pharma | $277M | 20% | PEAK | Stable | 11.4yr |
| 4 | TYMLOS (ABALOPARATIDE) | Radius Health | $198M | 14% | PEAK | Stable | 13.7yr |
Drug Class Breakdown
LOE approaching; potential for new mechanisms
Mature, multiple generics; limited differentiation
Growth trajectory through 2037
Stable; multiple biosimilars in market
Emerging niche for rare endocrine disorders
Career Outlook
StableEndocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.
Breaking In
Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.
For Experienced Professionals
Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.
In-Demand Skills
Best For
Hiring Landscape
Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).
By Department
Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.
On Market (5)
Approved therapies currently available
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (9)
Total enrollment: 1,097 patients across 9 trials
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Mifepristone in Children With Refractory Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Related Jobs in Endocrinology
Group Leader - Senior Director, Quantitative Pharmacology and Pharmacometrics (Hybrid or Remote)
Director, Marketing Operations
SPM
Sr. Consultant, Data Analyst & Commercial Productivity
Area Business Manager - Central Alabama
Grants Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.